Eric Morgen - 17 Feb 2026 Form 4 Insider Report for BioAge Labs, Inc. (BIOA)

Reporting relationship: Chief Operating Officer, Director
Issuer ticker: BIOA
Reported as of: 17 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 Feb 2026, 16:40:40 UTC
Prior SEC filing: 25 Feb 2025
Source filing: View source filing
Reporting owner signature: /s/ Dov A. Goldstein as attorney-in-fact

Key filing fact

Eric Morgen filed Form 4 for BioAge Labs, Inc. (BIOA) on 19 Feb 2026.

Key facts

This page summarizes Eric Morgen's Form 4 filing for BioAge Labs, Inc. (BIOA).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 19 Feb 2026, 16:40.

Change

Previous filing in this sequence was filed on 25 Feb 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002036289 Primary reporting owner

Morgen Eric

Relationship: Chief Operating Officer, Director
Address: C/O BIOAGE LABS, INC., 5885 HOLLIS STREET, SUITE 370, EMERYVILLE
Signature: /s/ Dov A. Goldstein as attorney-in-fact
Signature date: 19 Feb 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BIOA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +110,000
Change %
Price: $0.000000
Shares after: 110,000
Date: 17 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 110,000
Exercise price: $19.63
Footnotes: F1

BIOA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +12,500
Change %
Price: $0.000000
Shares after: 12,500
Date: 17 Feb 2026
Ownership: By Spouse
Underlying class: Common Stock
Underlying amount: 12,500
Exercise price: $19.63
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

Footnote F2

The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the holder's continued service to the Issuer on each vesting date.

Footnote F3

Represents an employee stock option directly held by the reporting person's spouse.